Madrigal Pharmaceuticals Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bullish stance on Madrigal Pharmaceuticals MDGL.

And retail traders should know.

We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.

Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MDGL, it often means somebody knows something is about to happen.

So how do we know what these investors just did?

Today, Benzinga's options scanner spotted 19 uncommon options trades for Madrigal Pharmaceuticals.

This isn't normal.

The overall sentiment of these big-money traders is split between 63% bullish and 36%, bearish.

Out of all of the special options we uncovered, 6 are puts, for a total amount of $1,146,930, and 13 are calls, for a total amount of $3,771,700.

What's The Price Target?

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $200.0 to $330.0 for Madrigal Pharmaceuticals over the recent three months.

Insights into Volume & Open Interest

Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Madrigal Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Madrigal Pharmaceuticals's whale trades within a strike price range from $200.0 to $330.0 in the last 30 days.

Madrigal Pharmaceuticals Call and Put Volume: 30-Day Overview

Biggest Options Spotted:

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

After a thorough review of the options trading surrounding Madrigal Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Where Is Madrigal Pharmaceuticals Standing Right Now?

• With a volume of 168,418, the price of MDGL is up 1.38% at $266.3.
• RSI indicators hint that the underlying stock may be approaching overbought.
• Next earnings are expected to be released in 55 days.

Professional Analyst Ratings for Madrigal Pharmaceuticals

Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $275.4.

• Reflecting concerns, an analyst from JMP Securities lowers its rating to Market Outperform with a new price target of $347.
• An analyst from Canaccord Genuity persists with their Buy rating on Madrigal Pharmaceuticals, maintaining a target price of $338.
• In a cautious move, an analyst from B. Riley Securities downgraded its rating to Sell, setting a price target of $155.
• An analyst from Citigroup downgraded its action to Buy with a price target of $382.
• In a cautious move, an analyst from B. Riley Securities downgraded its rating to Sell, setting a price target of $155.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Madrigal Pharmaceuticals options trades with real-time alerts from Benzinga Pro.